Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 16/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | PTGFR | P43088 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491656 | 0.87 | PTGFR (0.49) | PDE10ATSHRDHODHPTGFR | |
| SCHEMBL2515841 | 0.80 | DHODH (0.52) | DHODHPTGFR | |
| SCHEMBL2807617 | 0.76 | PDE10A (0.77) | PDE10ATSHRDHODHDHFRALKBH5 | |
| SCHEMBL2514667 | 0.75 | DHODH (0.59) | PDE10ATSHRDHODHPTGFR | |
| SCHEMBL18075791 | 0.75 | PDE10A (0.75) | PDE10ATSHRDHODHDHFRALKBH5 | |
| SCHEMBL2373140 | 0.72 | DHODH (0.59) | PDE10ATSHRDHODHPTGFR | |
| SCHEMBL2372015 | 0.72 | DHODH (0.56) | PDE10ATSHRDHODHPTGFR | |
| SCHEMBL2494525 | 0.72 | PDE10A (0.58) | PDE10ATSHRDHODH | |
| SCHEMBL17593890 | 0.71 | DHODH (0.72) | PDE10ATSHRDHODHPTGFR | |
| SCHEMBL5425219 | 0.71 | DHODH (0.72) | PDE10ATSHRDHODHDHFRALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549872-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8658636-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2549872-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130012499-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011119701-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012499-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV5 | PDE10A 2268/4885TSHR 2692/4885DHODH 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.